Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection

Published on Apr 20, 2018in European Radiology4.101
· DOI :10.1007/S00330-018-5410-6
Giovanni Marchegiani29
Estimated H-index: 29
Valentina Todaro2
Estimated H-index: 2
+ 7 AuthorsClaudio Bassi110
Estimated H-index: 110
Objectives To assess factors associated with radical resection (R0) of pancreatic ductal adenocarcinoma (PDAC) after induction treatment with FOLFIRINOX.
📖 Papers frequently viewed together
4,268 Citations
6 Citations
62 Citations
#1Mathilde Wagner (Paris IV: Paris-Sorbonne University)H-Index: 1
#1Mathilde Wagner (Paris IV: Paris-Sorbonne University)H-Index: 20
Last. Jean-Baptiste BachetH-Index: 35
view all 8 authors...
Aim To assess anatomic changes on computed tomography (CT) after neoadjuvant FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) chemotherapy for secondary resected borderline resectable (BR) and locally advanced (LA) pancreatic adenocarcinoma and their accuracy to predict resectability and pathological response.
62 CitationsSource
#1Oliver Strobel (University Hospital Heidelberg)H-Index: 50
#2Thomas HankH-Index: 11
Last. M. W. BüchlerH-Index: 5
view all 10 authors...
Objective:To assess the relevance of resection margin status for survival outcome after resection and adjuvant therapy for pancreatic cancer.Background:The definitions for R0 and R1 margin status after resection for pancreatic cancer are controversial. The strict definition of R0 requiring a 1 mm tu
140 CitationsSource
#1Mustafa Suker (EUR: Erasmus University Rotterdam)H-Index: 12
#2Berend R Beumer (EUR: Erasmus University Rotterdam)H-Index: 3
Last. Bas Groot Koerkamp (EUR: Erasmus University Rotterdam)H-Index: 40
view all 20 authors...
Summary Background 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. Several studies have examined systemic chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patients with locally advanced pancreatic cancer. We aimed to assess the effectiveness of FOLFIRINOX as first-line treatment in this patient population. Methods We systematically searched Embase, MEDLINE (OvidSP), Web of Science, Scopus, PubMed Publish...
411 CitationsSource
#1Nikolaos Kartalis (KI: Karolinska Institutet)H-Index: 18
Last. Nikolaos Papanikolaou (KI: Karolinska Institutet)H-Index: 8
view all 8 authors...
Abstract Objectives To compare two Gaussian diffusion-weighted MRI (DWI) models including mono-exponential and bi-exponential, with the non-Gaussian kurtosis model in patients with pancreatic ductal adenocarcinoma. Materials and methods After written informed consent, 15 consecutive patients with pancreatic ductal adenocarcinoma underwent free-breathing DWI (1.5T, b-values: 0, 50, 150, 200, 300, 600 and 1000s/mm 2 ). Mean values of DWI-derived metrics ADC, D, D*, f, K and D K were calculated fro...
22 CitationsSource
#1Ulrich Nitsche (TUM: Technische Universität München)H-Index: 24
#2Patrick Wenzel (TUM: Technische Universität München)H-Index: 9
Last. Jörg Kleeff (TUM: Technische Universität München)H-Index: 94
view all 13 authors...
Background FOLFIRINOX is an active but relatively toxic chemotherapeutic regimen for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The increased frequency of responding tumors shift interest to neoadjuvant approaches. We report our institutional experience with FOLFIRINOX for therapy-naive patients with locally advanced and initially unresectable PDAC.
52 CitationsSource
#1John Chang (University of Texas MD Anderson Cancer Center)H-Index: 7
#2Donald F. Schomer (University of Texas MD Anderson Cancer Center)H-Index: 15
Last. Tomislav Dragovich (University of Texas MD Anderson Cancer Center)H-Index: 21
view all 3 authors...
Pancreatic adenocarcinoma is one of the deadliest human malignancies. Early detection is difficult and effective treatment is limited. Verifying the presence of micrometastatic dissemination and vessel invasion remains elusive, limiting radiological staging once this diagnosis is made. Diagnostic imaging provides independent tools to evaluate and characterize the biologic behavior of pancreatic cancer. Conventional anatomic imaging alone with either CT or MRI yields useful information on organ i...
12 CitationsSource
#1Cristina R. Ferrone (Harvard University)H-Index: 77
#2Giovanni Marchegiani (Harvard University)H-Index: 29
view all 21 authors...
The prevalence of pancreatic adenocarcinoma (PDAC) continues to increase. The American Cancer Society predicts 46,420 new cases and 39,590 deaths in the United States in 2014. The majority of patients present with metastatic disease, whereas 30% present with locally advanced (LA) cancers.1 Unfortunately, overall survival (OS) of pancreatic cancer patients remains low, with surgical resection offering the only chance for potential cure. However, even then the OS is reported to be less than 20%.2–...
479 CitationsSource
#1M Barral (French Institute of Health and Medical Research)H-Index: 1
#1Matthias BarralH-Index: 9
Last. P. SoyerH-Index: 14
view all 10 authors...
Although diffusion-weighted (DW) MR imaging is still at an early stage of investigation as a tool for the evaluation of the pancreas, evidence from published literature suggests that DW MR imaging has a potential to depict and characterize a variety of focal pancreatic lesions.
137 CitationsSource
#1Aparna Balachandran (University of Texas MD Anderson Cancer Center)H-Index: 22
#2Priya Bhosale (University of Texas MD Anderson Cancer Center)H-Index: 28
Last. Eric P. Tamm (University of Texas MD Anderson Cancer Center)H-Index: 40
view all 4 authors...
Abstract Ductal adenocarcinoma accounts for 85% to 90% of all solid pancreatic neoplasms, is increasing in incidence, and is the fourth leading cause of cancer-related deaths. There are currently no screening tests available for the detection of ductal adenocarcinoma. The only chance for cure in pancreatic adenocarcinoma is surgery. Imaging has a crucial role in the identification of the primary tumor, vascular variants, identification of metastases, disease response assessment to treatment, and...
23 CitationsSource
#1Kyle C. Cuneo (UM: University of Michigan)H-Index: 24
#2Thomas L. Chenevert (UM: University of Michigan)H-Index: 84
Last. Brian D. Ross (UM: University of Michigan)H-Index: 76
view all 16 authors...
PURPOSE: In the current study we examined the ability of diffusion MRI (dMRI) to predict pathologic response in pancreatic cancer patients receiving neoadjuvant chemoradiation. METHODS: We performed a prospective pilot study of dMRI in patients with resectable pancreatic cancer. Patients underwent dMRI prior to neoadjuvant chemoradiation. Surgical specimens were graded according to the percent tumor cell destruction. Apparent diffusion coefficient (ADC) maps were used to generate whole-tumor der...
49 CitationsSource
Cited By17
#1Hyun Kyung Yang (Yonsei University)H-Index: 10
#2Mi-Suk Park (Yonsei University)H-Index: 44
Last. Sang Hyun Choi (UOU: University of Ulsan)H-Index: 20
view all 8 authors...
To assess the CT diagnostic performance for evaluating resectability of pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy and identify the factor(s) that affect(s) diagnostic performance. Databases were searched to identify studies published from January 1, 2000, to November 5, 2019 that evaluated the CT diagnostic performance for assessing resectability of post-neoadjuvant PDAC. Two reviewers independently extracted data and assessed the study quality. A meta-analysis was perfor...
#1Fumihito Toshima (Kanazawa University)H-Index: 7
#2Dai Inoue (Kanazawa University)H-Index: 20
Last. Toshifumi Gabata (Kanazawa University)H-Index: 52
view all 7 authors...
OBJECTIVES To determine the correlation between CT-diagnosed extra-pancreatic extension of pancreatic ductal adenocarcinoma (PDAC), pathology-diagnosed extra-pancreatic extension, and survival in patients with PDAC. METHODS This retrospective study included 87 patients with resected PDAC. Two radiologists evaluated negative ((i) tumours surrounded by the pancreatic parenchyma and (ii) tumours contacting the pancreatic surface) or positive ((iii) tumours with peri-pancreatic strand appearances an...
#1Sae Jin Park (Seoul National University Hospital)H-Index: 3
#2Jung Hoon Kim (SNU: Seoul National University)H-Index: 23
Last. Joon Koo Han (SNU: Seoul National University)H-Index: 74
view all 5 authors...
To investigate important factors for recurrence-free survival (RFS) and overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDA) who underwent surgery after neoadjuvant FOLFIRINOX using CT and histopathological findings. Sixty-nine patients with PDA who underwent surgery after neoadjuvant FOLFIRINOX were retrospectively included. All patients underwent baseline and first follow-up CT. Two reviewers assessed the CT findings and resectability based on the NCCN guideline. They ...
1 CitationsSource
#1Sohee Park (UOU: University of Ulsan)H-Index: 4
#2Jong Keon Jang (UOU: University of Ulsan)H-Index: 5
Last. Seong Ho Park (UOU: University of Ulsan)H-Index: 66
view all 8 authors...
We aimed to systematically evaluate the diagnostic accuracy of CT-determined resectability following neoadjuvant treatment for predicting margin-negative resection (R0 resection) in patients with pancreatic ductal adenocarcinoma (PDAC). Original studies with sufficient details to obtain the sensitivity and specificity of CT-determined resectability following neoadjuvant treatment, with a reference on the pathological margin status, were identified in PubMed, EMBASE, and Cochrane databases until ...
2 CitationsSource
#1Giampaolo Perri (University of Texas MD Anderson Cancer Center)H-Index: 9
#2Laura R. Prakash (University of Texas MD Anderson Cancer Center)H-Index: 15
Last. Matthew H.G. KatzH-Index: 66
view all 17 authors...
OBJECTIVE: We sought to identify potential radiologic and serologic markers of pancreatic tumor response to therapy, using pathologic major response (pMR) as the objective endpoint. BACKGROUND: We previously demonstrated that a pMR to preoperative therapy, defined as detection of <5% viable cancer cells in the surgical specimen on histopathological analysis, is an important prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Pretreatment and posttreatment comput...
26 CitationsSource
#1Jong Keon Jang (UOU: University of Ulsan)H-Index: 5
#2Jae Ho Byun (UOU: University of Ulsan)H-Index: 28
Last. Moon-Gyu Lee (UOU: University of Ulsan)H-Index: 53
view all 13 authors...
We aimed to assess the ability of CT-determined resectability, as defined by a recent version of NCCN criteria, and associated CT findings to predict margin-negative (R0) resection in patients with PDAC after neoadjuvant FOLFIRINOX chemotherapy. Sixty-four patients (36 men and 28 women; mean age, 58.8 years) with borderline resectable or unresectable PDAC who received neoadjuvant FOLFIRINOX were evaluated retrospectively. CT findings were independently assessed by two abdominal radiologists acco...
6 CitationsSource
#1Shimaa Abdalla Ahmed (Assiut University)H-Index: 3
#2Amr F. Mourad (Assiut University)H-Index: 3
Last. Murad A. Jabir (Kyoto University)H-Index: 4
view all 9 authors...
OBJECTIVES To assess the utility of MDCT tumor-vascular interface criteria for predicting vascular invasion and resectability in borderline pancreatic cancer (BRPC) patients after neoadjuvant therapy (NAT). METHODS This prospective study included 90 patients with BRPC who finished NAT, showed no progression in preoperative CTs and underwent surgery. Two radiologists independently assessed preoperative vessel-tumor interface criteria. The area under the ROC curve (AUC) was used to evaluate the di...
2 CitationsSource
#1Hyungjin Rhee (Yonsei University)H-Index: 17
#2Mi-Suk Park (Yonsei University)H-Index: 44
In pancreatic cancer, imaging plays an essential role in surveillance, diagnosis, resectability evaluation, and treatment response evaluation. Pancreatic cancer surveillance in high-risk individuals has been attempted using endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI). Imaging diagnosis and resectability evaluation are the most important factors influencing treatment decisions, where computed tomography (CT) is the preferred modality. EUS, MRI, and positron emission tomography...
4 CitationsSource
#1Zhen J. Wang (UCSF: University of California, San Francisco)H-Index: 29
#2Hina Arif-Tiwari (UA: University of Arizona)H-Index: 9
Last. Avinash Kambadakone (Harvard University)H-Index: 25
view all 13 authors...
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related death in the United States and is projected to be the second by 2030. Systemic combination chemotherapy is considered an essential first-line treatment for the majority of patients with PDA, in both the neoadjuvant and palliative settings. In addition, a number of novel therapies are being tested in clinical trials for patients with advanced PDA. In all cases, accurate and timely assessment of treatment response ...
1 CitationsSource
#1Mariya Kobi (Montefiore Medical Center)H-Index: 7
#2Gregory Veillette (WMC: Westchester Medical Center)H-Index: 1
Last. Milana Flusberg (WMC: Westchester Medical Center)H-Index: 9
view all 8 authors...
Abstract Pancreatic cancer is an aggressive disease with rising incidence and high mortality despite advances in imaging and therapeutic options. Surgical resection is currently the only curative treatment, with expanding roles for adjuvant and neoadjuvant chemo-radiation. Accurate detection, staging, and post-treatment monitoring of pancreatic cancer is critical to improving survival and imaging plays a central role in the multidisciplinary approach to this disease. This article will provide a ...